Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/40—Cyclodextrins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
  • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Inorganic Chemistry (AREA)
• Nanotechnology (AREA)
• Medical Informatics (AREA)
• Biophysics (AREA)
• Crystallography & Structural Chemistry (AREA)
• Molecular Biology (AREA)
• General Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Anesthesiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (4)

Publications (1)

Family

ID=44306295

Family Applications (1)

Country Status (27)

Families Citing this family (25)

Family Cites Families (11)

• 2011
  • 2011-01-19 US US13/574,201 patent/US8697678B2/en active Active
  • 2011-01-19 KR KR1020127021761A patent/KR101747476B1/ko active Active
  • 2011-01-19 PT PT117342451T patent/PT2525798T/pt unknown
  • 2011-01-19 JP JP2012549208A patent/JP5930311B2/ja active Active
  • 2011-01-19 SM SM20170518T patent/SMT201700518T1/it unknown
  • 2011-01-19 LT LTEP11734245.1T patent/LT2525798T/lt unknown
  • 2011-01-19 CA CA2786762A patent/CA2786762C/en active Active
  • 2011-01-19 NO NO11734245A patent/NO2525798T3/no unknown
  • 2011-01-19 ES ES11734245.1T patent/ES2646829T3/es active Active
  • 2011-01-19 GB GB1201842.0A patent/GB2484244B/en active Active
  • 2011-01-19 SI SI201131342T patent/SI2525798T1/en unknown
  • 2011-01-19 RU RU2012134321/15A patent/RU2574022C2/ru active
  • 2011-01-19 CN CN201180013975.2A patent/CN102802635B/zh active Active
  • 2011-01-19 EP EP11734245.1A patent/EP2525798B1/en active Active
  • 2011-01-19 PL PL11734245T patent/PL2525798T3/pl unknown
  • 2011-01-19 DK DK11734245.1T patent/DK2525798T3/da active
  • 2011-01-19 HU HUE11734245A patent/HUE035441T2/en unknown
  • 2011-01-19 GB GB1210657.1A patent/GB2491491B/en active Active
  • 2011-01-19 HR HRP20171699TT patent/HRP20171699T1/hr unknown
  • 2011-01-19 NZ NZ601255A patent/NZ601255A/xx not_active IP Right Cessation
  • 2011-01-19 AU AU2011207103A patent/AU2011207103B2/en active Active
  • 2011-01-19 SG SG2012050159A patent/SG181997A1/en unknown
  • 2011-01-19 WO PCT/AU2011/000050 patent/WO2011088503A1/en not_active Ceased
  • 2011-01-19 RS RS20171135A patent/RS56576B1/sr unknown
  • 2011-01-19 BR BR112012017800-8A patent/BR112012017800B1/pt not_active IP Right Cessation
• 2012
  • 2012-07-18 ZA ZA2012/05370A patent/ZA201205370B/en unknown
  • 2012-07-20 CL CL2012002032A patent/CL2012002032A1/es unknown
• 2013
  • 2013-11-01 US US14/069,751 patent/US8975245B2/en active Active
• 2017
  • 2017-11-07 CY CY20171101164T patent/CY1119947T1/el unknown

Also Published As

Similar Documents